

Mettine H A Bos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6302631/publications.pdf>

Version: 2024-02-01

54
papers

875
citations

394286

19
h-index

501076

28
g-index

55
all docs

55
docs citations

55
times ranked

1066
citing authors

#	ARTICLE	IF	CITATIONS
1	Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 328-338.	1.9	4
2	Lower-leg injury and knee arthroscopy have distinct effects on coagulation. <i>Blood Advances</i> , 2022, 6, 5232-5243.	2.5	2
3	High Soluble Thrombomodulin Is Associated with an Increased Risk of Major Bleeding during Treatment with Oral Anticoagulants: A Caseâ€”Cohort Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 070-075.	1.8	1
4	Elevated anti-human factor Xa activity in rabbit and rodent plasma: Implications for preclinical assessment of human factor X in animal models of hemostasis. <i>Thrombosis Research</i> , 2021, 198, 154-162.	0.8	4
5	Structureâ€”function of anticoagulant TIXâ€”5, the inhibitor of factor Xaâ€”mediated FV activation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1697-1708.	1.9	1
6	Evolutionary adaptation of the Î³â€”carboxyglutamic acid domain in blood coagulation factor X in the Serpentes suborder. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
7	Pharmacological Characterisation of Pseudocerastes and Eristicophis Viper Venoms Reveal Anticancer (Melanoma) Properties and a Potentially Novel Mode of Fibrinogenolysis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6896.	1.8	9
8	ptFVa (<i>Pseudonaja Textilis</i> Venom-Derived Factor Va) Retains Structural Integrity Following Proteolysis by Activated Protein C. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2263-2276.	1.1	0
9	Enhanced functional recombinant factor IX production by human embryonic kidney cells engineered to overexpress VKORC1. <i>Biotechnology Progress</i> , 2020, 36, e2938.	1.3	3
10	Coagulopathy after hemorrhagic traumatic brain injury, an observational study of the incidence and prognosis. <i>Acta Neurochirurgica</i> , 2020, 162, 329-336.	0.9	29
11	Vitamin K therapy to reduce bleeding. <i>Blood</i> , 2020, 136, 780-782.	0.6	2
12	Association Between Hepatic Triglyceride Content and Coagulation Factors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 3004-3014.	1.1	3
13	Evolutionary Adaptations in Pseudonaja Textilis Venom Factor X Induce Zymogen Activity and Resistance to the Intrinsic Tenase Complex. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1512-1523.	1.8	5
14	Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 986-998.	1.5	7
15	Clinical implications of coagulotoxic variations in Mamushi (Viperidae: Gloydius) snake venoms. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2019, 225, 108567.	1.3	22
16	Illustrated Stateâ€”ofâ€”theâ€”Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 431-497.	1.0	11
17	Improved activity and expression of recombinant human factor IX by propeptide engineering. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2019, 27, 653-660.	0.9	3
18	Clinical implications of differential antivenom efficacy in neutralising coagulotoxicity produced by venoms from species within the arboreal viperid snake genus <i>Trimeresurus</i> . <i>Toxicology Letters</i> , 2019, 316, 35-48.	0.4	27

#	ARTICLE	IF	CITATIONS
19	Snakebites and microvesicles: Popping bubbles. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 156-157.	1.0	1
20	Blood coagulation factor Va's key interactive residues and regions for prothrombinase assembly and prothrombin binding. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1229-1239.	1.9	33
21	Coagulotoxic effects by brown snake (<i>Pseudonaja</i>) and taipan (<i>Oxyuranus</i>) venoms, and the efficacy of a new antivenom. <i>Toxicology in Vitro</i> , 2019, 58, 97-109.	1.1	30
22	Basal but divergent: Clinical implications of differential coagulotoxicity in a clade of Asian vipers. <i>Toxicology in Vitro</i> , 2019, 58, 195-206.	1.1	30
23	Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 319-328.	1.9	25
24	Habu coagulotoxicity: Clinical implications of the functional diversification of Protobothrops snake venoms upon blood clotting factors. <i>Toxicology in Vitro</i> , 2019, 55, 62-74.	1.1	27
25	High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 99-109.	1.9	77
26	Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A. <i>Blood</i> , 2019, 134, 1110-1110.	0.6	0
27	Elevated coagulation factor levels affect the tissue factor-threshold in thrombin generation. <i>Thrombosis Research</i> , 2018, 172, 104-109.	0.8	10
28	Factor V levels and risk of venous thrombosis: The MEGA case-control study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 320-326.	1.0	10
29	Lipid levels and risk of venous thrombosis: results from the MEGA-study. <i>European Journal of Epidemiology</i> , 2017, 32, 669-681.	2.5	35
30	Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors. <i>Nature Communications</i> , 2017, 8, 528.	5.8	27
31	Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists. <i>PLoS ONE</i> , 2016, 11, e0164485.	1.1	16
32	Efficient expression of functional human coagulation factor IX in stably-transfected <i>Drosophila melanogaster</i> S2 cells; comparison with the mammalian CHO system. <i>Biotechnology Letters</i> , 2016, 38, 1691-1698.	1.1	8
33	Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences in mammalian cell line. <i>Biotechnology Letters</i> , 2015, 37, 1773-1781.	1.1	10
34	Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa-Inhibitors. <i>Blood</i> , 2015, 126, 126-126.	0.6	0
35	Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1647-1657.	1.9	60
36	Functional implications of the unique disulfide bond in venom factor V from the Australian common brown snake <i>Pseudonaja textilis</i> . <i>Toxin Reviews</i> , 2014, 33, 37-41.	1.5	1

#	ARTICLE	IF	CITATIONS
37	Restoring the Procofactor State of Factor Va-like Variants by Complementation with B-domain Peptides. <i>Journal of Biological Chemistry</i> , 2013, 288, 30151-30160.	1.6	28
38	A Bipartite Autoinhibitory Region within the B-domain Suppresses Function in Factor V. <i>Journal of Biological Chemistry</i> , 2012, 287, 26342-26351.	1.6	51
39	Evolutionary conservation of the tissue factor disulfide bonds and identification of a possible oxidoreductase binding motif. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 161-162.	1.9	3
40	Expression of biologically active human clotting factor IX in <i>Drosophila</i> S2 cells: γ -carboxylation of a human vitamin K-dependent protein by the insect enzyme. <i>Biotechnology Progress</i> , 2012, 28, 45-51.	1.3	29
41	Modulating the Factor V Procofactor to Cofactor Transition Using Recombinant B-Domain Fragments. <i>Blood</i> , 2011, 118, 376-376.	0.6	0
42	Procoagulant Adaptation of a Blood Coagulation Prothrombinase-like Enzyme Complex in Australian Elapid Venom. <i>Toxins</i> , 2010, 2, 1554-1567.	1.5	20
43	Molecular Mechanism Underlying the Need for Three Cleavage Sites within the B-Domain to Activate Factor V by Thrombin. <i>Blood</i> , 2010, 116, 2219-2219.	0.6	0
44	Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation. <i>Journal of Coagulation Disorders</i> , 2010, 2, 19-27.	0.0	14
45	The molecular basis of factor V and VIII procofactor activation. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1951-1961.	1.9	80
46	Venom factor V from the common brown snake escapes hemostatic regulation through procoagulant adaptations. <i>Blood</i> , 2009, 114, 686-692.	0.6	40
47	Response: Response to "Clinical relevance of brown snake (<i>Pseudonaja</i> spp) factor V escaping hemostatic regulation". <i>Blood</i> , 2009, 114, 2563-2564.	0.6	1
48	Conserved Structural Motifs Cooperate to Maintain Blood Coagulation Factor V in An Inactive Procofactor State.. <i>Blood</i> , 2009, 114, 850-850.	0.6	0
49	Evolutionary Adaptation of Factor V from the Venom of the Common Brown Snake into a Potent Procoagulant. <i>Blood</i> , 2008, 112, 586-586.	0.6	2
50	Venom-Derived Factor V from the Common Brown Snake <i>P. Textilis</i> Is Expressed as a Constitutively Active Cofactor.. <i>Blood</i> , 2007, 110, 1765-1765.	0.6	0
51	Destabilization of the Factor V B-Domain Results in Procofactor Activation.. <i>Blood</i> , 2006, 108, 198-198.	0.6	1
52	Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma?. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 522-530.	1.9	24
53	Acyl-coenzyme A: Cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7 α -hydroxylase in cultured rat hepatocytes and in vivo in the rat. <i>Hepatology</i> , 1999, 30, 491-500.	3.6	47
54	Effect of prepropeptide replacement on γ -carboxylation and activity of recombinant coagulation factor IX. <i>Biotechnology Letters</i> , 0, , .	1.1	0